

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	Colombo et al.	:	Confirmation No.: 2887
APPLICATION NO.:	10/714,166	:	Examiner: E. Peselev
FILING DATE:	November 14, 2003	:	Group Art Unit: 1623
TITLE:	DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS	:	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a)

A Request for Continued Examination (RCE) for the subject application was filed on October 30, 2007; however, the RCE did not include a responsive amendment. A Notice of Improper Request for Continued Examination was mailed on December 10, 2007 (Notice), which indicated that the RCE filed on October 30, 2007 was improper, because it was not accompanied by a submission as required by 37 C.F.R. § 1.114. The Notice also indicated that the time period for responding to the final office action continues to run from the mailing date of the final office action, i.e., July 13, 2007.

A response to the final office action was initially set to initially expire three (3) months from the mailing date of the final office action, i.e., October 13, 2007. Pursuant to the provisions of 37 C.F.R. §1.136(a), Applicants request that the time period for filing this response to the final office action be extended by three (3) months such that it expires on January 13, 2008. Applicants note that a Petition for Extension of Time Pursuant to 37 C.F.R. §1.136(a) was filed on October 30, 2007, which included the requisite fee for a one (1) month extension of time (\$120.00). Thus, the fee required for filing a three (3) month extension of time is believed to be \$930, that is, the fee as stated under 37 C.F.R. §1.17 or a three (3) month extension of time (\$1050.00) reduced by the fee of the one (1) month extension of time that was paid on October 30, 2007 (\$120.00).

Authorization is hereby provided to charge the amount \$930.00 as well as any additional fees required, or to credit any overpayment to Applicants' Deposit Account No. 16-1445.

Respectfully submitted,

Date: January 8, 2008

/David L. Kershner/
David L. Kershner
Attorney for Applicant
Reg. No. 53,112

Pfizer Inc
Patent Dept. – 5th Floor
150 East 42nd Street
New York, NY 10017-5612
(212) 733-0538